The year 2026 represents a "Great Rationalisation" for the European HealthTech and MedTech sector. The era of easy money, regulatory ambiguity, and "growth at all costs" is over. It has been replaced by a landscape defined by industrial rigor, regulatory enforcement, and financial discipline. For founders, the path to maximising shareholder value lies not in chasing hype cycles, but in building robust, compliant, and efficient infrastructure. It requires a mastery of the "bo

The digital health ecosystem is witnessing the commercial maturation of intermediated business models, yet a critical distinction must be drawn between distribution channels and value origination. The business-to-business-to-consumer (B2B2C) model, characterised by partnerships between HealthTech companies and enterprise payers (employers, insurers), has become the default go-to-market strategy, primarily due to its ability to scale adoption and mitigate high customer acquisi

The European healthcare technology (HealthTech) mergers and acquisitions (M&A) market is navigating a period of cautious yet discernible rebound in 2025. This resurgence is primarily propelled by improving macroeconomic conditions, substantial private equity dry powder and a pervasive strategic imperative for digital transformation across the healthcare ecosystem.